Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04291105 · ClinicalTrials.gov registry record · Phase 2

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

A Phase 2 study of Melanoma and Head and Neck Squamous Cell Carcinoma, sponsored by Vyriad.

Recruiting
Registry status
Phase 2
Development phase
87
Enrollment target
20
Study locations

NCT04291105 is a Phase 2 study of Melanoma and Head and Neck Squamous Cell Carcinoma that is actively recruiting participants, run by Vyriad. The registered enrollment target is 87 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04291105, a Phase 2 study of Melanoma and Head and Neck Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Vyriad.

RECRUITING
Registry status
Phase 2
Development phase
87 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment.

Conditions Studied

Melanoma Head and Neck Squamous Cell Carcinoma Colo-rectal Cancer

Interventions

  • BIOLOGICAL Cemiplimab
  • BIOLOGICAL VV1

Study Locations (20)

California

  • City of Hope Medical Center - Durate
  • USC Norris Comprehensive Cancer Center - Los Angeles
  • HOAG Memorial Hospital Presbyterian - Newport Beach
  • Saint John's Health Center - John Wayne Cancer Institute (JWCI) - Santa Monica
  • Stanford Health Care - Stanford

Florida

  • Mayo Clinical - Jacksonville
  • University of Miami - Miami

Minnesota

  • Masonic Cancer Center, University of Minnesota - Minneapolis
  • Mayo Clinic - Rochester

New Jersey

  • Atlantic Health - Morristown
  • Rutgers Cancer Institute of New Jersey - New Brunswick

Ohio

  • University of Cincinnati Medical Center - Cincinnati
  • Ohio State University - Columbus

Arizona

  • Mayo Clinical - Phoenix

Connecticut

  • Yale University - New Haven

District of Columbia

  • Georgetown University Medical Center - Washington D.C.

Trial Details

FieldValue
Enrollment Target 87 participants
Start Date 2020-04-24
Est. Completion 2025-12
Phase Phase 2

Sponsor

Vyriad

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04291105

The ClinicalTrials.gov registry entry for NCT04291105 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (88% lower). The listed sponsor is Vyriad, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Cemiplimab is the first listed.

NCT04291105 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Minnesota.

Frequently Asked Questions

What is clinical trial NCT04291105 about?

NCT04291105 is a clinical study titled "Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients". This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are ...

What is the current status of trial NCT04291105?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2020-04-24. Estimated completion is 2025-12.

What conditions does trial NCT04291105 study?

This clinical trial studies the following conditions: Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer.

What interventions are being tested in trial NCT04291105?

The interventions under investigation include: Cemiplimab (BIOLOGICAL), VV1 (BIOLOGICAL).

Who is sponsoring clinical trial NCT04291105?

This trial is sponsored by Vyriad, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04291105 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Melanoma

All registered trials for this condition

Head and Neck Squamous Cell Carcinoma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.